NYSE:BMYPharmaceuticals
Promising Lung Cancer Trial Results Could Be a Game Changer for Bristol-Myers Squibb (BMY)
BioNTech SE and Bristol-Myers Squibb announced promising interim data from a global Phase 2 trial evaluating pumitamig combined with chemotherapy in extensive-stage small cell lung cancer, presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona.
These results, including a high disease control rate and an encouraging safety profile, contributed to pumitamig receiving Orphan Drug designation in the US and ongoing advancement into Phase 3 trials across multiple countries.
We’ll...